Assessment of Cardiovascular Risk with the Use of Androgen Deprivation Therapy for Prostate Cancer

UroToday is excited to host a lecture from a leading cardiologist’s perspective, Dr. Matthew Roe from Duke Clinical Research Institute. Dr. Roe’s discussion features the topics: atherosclerotic plaque formation and plaque instability and incidences of prostate cancer and cardiovascular events. In addition, cardiovascular risks with androgen deprivation therapy, GNRH antagonists and GnRH agonists.

Biography:
Matthew T. Roe, MD, MHS

Faculty Director, Global Outcomes Commercial Megatrials
DCRI Fellowship Program Director
Associate Professor of Medicine

Duke Clinical Research Institute